These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Solitary plasmacytoma: 10 years' experience at All India Institute of Medical Sciences, New Delhi.
    Author: Baghmar S, Mohanti BK, Sharma A, Kumar L, Prakash G, Kumar S, Gupta R, Kumar R, Raina V.
    Journal: Leuk Lymphoma; 2013 Aug; 54(8):1665-70. PubMed ID: 23163525.
    Abstract:
    Plasma cell dyscrasias account for 1% of all malignancies and 10% of hematological malignancies. About 5% of patients with a plasma cell dyscrasia present with either solitary bone plasmacytoma (SBP) or, less commonly, a soft tissue mass, extramedullary plasmacytoma (EMP) of monoclonal plasma cells. In this study we present the clinical features, management and outcome of 60 patients with solitary plasmacytoma, who constituted 5.6% of 1129 patients with plasma cell dyscrasias treated over a 10-year period at All India Institute of Medical Sciences. Median age was 49 years. Fifty-two had SBP and eight had EMP. Forty-nine (82%) patients received radiotherapy with or without surgical excision or chemotherapy. Five-year event-free survival (EFS) and overall survival (OS) were 45.5% and 91%, respectively. Median EFS and OS were 38 and 122 months, respectively. Five-year survival rates in patients who developed multiple myeloma and those who did not were 81% and 100%, respectively. The median time of progression to myeloma was 21 months.
    [Abstract] [Full Text] [Related] [New Search]